Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab21 expands genetic testing deal with PGxHealth

This article was originally published in Clinica

Executive Summary

Diagnostic firm Lab21 has extended its partnership with the genomic testing unit of Clinical Data in order to offer its customers a wider range of genetic tests. Cambridge, UK-based Lab21 had an existing licence with Clinical Data’s PGxHealth subsidiary to exclusively market the Familion portfolio of mutation tests in the UK and Ireland, but has now added assays for catecholaminergic polymorphic ventricular tachycardia (CPVT) and hypertrophic cardiomyopathy (HCM) to its remit. The CPVT and HCM assays are compatible with the Familion platform and will also be marketed in the UK and Ireland. Financial terms of the deal were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel